In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining

1973 • 4,217 citations

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

1996 • 3,649 citations

Induction of Chronic Myelogenous Leukemia in Mice by the P210 ^bcr/abl Gene of the Philadelphia Chromosome

1990 • 2,207 citations

Fused transcript of abl and bcr genes in chronic myelogenous leukaemia

1985 • 1,650 citations

What is synergy?

1989 • 1,315 citations

Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products

1990 • 1,305 citations

Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity

1979 • 912 citations

Acute Lymphoblastic Leukemia

1998 • 816 citations

Taxol induces bcl-2 phosphorylation and death of prostate cancer cells.

1996 • 662 citations

The Tyrosine Kinase Inhibitor CGP57148B Selectively Inhibits the Growth of BCR-ABL–Positive Cells

1997 • 646 citations

Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia

1994 • 592 citations

Chronic Myelogenous Leukemia: Biology and Therapy

1999 • 483 citations

Chronic myelogenous leukemia: a concise update

1993 • 453 citations

In Vivo Eradication of Human BCR/ABL-Positive Leukemia Cells With an ABL Kinase Inhibitor

1999 • 388 citations

Interferon Alfa Versus Chemotherapy for Chronic Myeloid Leukemia: A Meta-analysis of Seven Randomized Trials

1997 • 282 citations

Effects of CPT‐11 in combination with other anti‐cancer agents in culture

1992 • 226 citations

Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group

1993 • 209 citations

Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission

2000 • 197 citations

Bcl-xL is phosphorylated in malignant cells following microtubule disruption.

1998 • 160 citations

Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells.

1993 • 157 citations

p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias

1996 • 151 citations

Sequential Homoharringtonine and Interferon- in the Treatment of Early Chronic Phase Chronic Myelogenous Leukemia

1999 • 98 citations

Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture.

1988 • 89 citations

Sequential Homoharringtonine and Interferon- in the Treatment of Early Chronic Phase Chronic Myelogenous Leukemia

1999 • 84 citations

The tyrosine kinase inhibitor STI571, like interferon-α, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia

2000 • 81 citations

The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.

2000 • 77 citations

In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines

1998 • 60 citations

Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia.

1992 • 44 citations

Homoharringtonine--perspectives on an active new natural product.

1986 • 34 citations

OPTIONS FOR THERAPY IN CHRONIC MYELOID LEUKAEMIA

1995 • 31 citations

Effects of amsacrine in combination with other anticancer agents in human acute lymphoblastic leukemia cells in culture

1991 • 22 citations

Treatment of Philadelphia‐chromosome‐positive human leukemia in scid mouse model with herbimycin A, bcr‐abl tyrosine kinase activity inhibitor

1995 • 20 citations

In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells

1994 • 17 citations

The susceptibility of Philadelphia chromosome positive cells to FAS‐mediated apoptosis is not linked to the tyrosine kinase activity of BCR‐ABL

1998 • 14 citations

In vitro sensitivity of human hematopoietic progenitor cells to 4-hydroperoxycyclophosphamide.

1993 • 10 citations

Acycloguanosine and herbimycin A co-operatively inhibit proliferation and induce erythrodifferentiation of human myeloid leukemia K562 cells

1994 • 1 citations